Back to top
more

WAVE Life Sciences (WVE)

(Delayed Data from NSDQ)

$4.66 USD

4.66
407,036

-0.08 (-1.69%)

Updated Apr 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 37.50% and 173.49%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -550% and 72.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After Plunging -23.26% in 4 Weeks, Here's Why the Trend Might Reverse for Wave Life Sciences (WVE)

Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Q3 Earnings and Revenues Lag Estimates

Heska (HSKA) delivered earnings and revenue surprises of -8.89% and 11.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wave Therapeutics (WVE) Up on Update From Huntington's Study

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 53.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -29.79% and 90.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of 55.12% and 164.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?